Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 291 Shares

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 291 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $12,128.88. Following the completion of the transaction, the senior vice president now directly owns 130,621 shares in the company, valued at $5,444,283.28. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Paula Green also recently made the following trade(s):

• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total value of $37,555.38.
• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $7,294.40.

Twist Bioscience Trading Up 4.8 %

NASDAQ:TWST opened at $44.94 on Tuesday. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a market cap of $2.68 billion, a P/E ratio of -13.30 and a beta of 2.15. The business has a 50 day moving average price of $45.42 and a two-hundred day moving average price of $45.31.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the prior year, the company posted ($0.75) earnings per share. The firm’s revenue was up 24.1% on a year-over-year basis. As a group, analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on TWST. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience in the third quarter valued at approximately $34,000. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of Twist Bioscience in the fourth quarter valued at $43,000. GF Fund Management CO. LTD. acquired a new position in Twist Bioscience during the fourth quarter worth $58,000. Finally, US Bancorp DE raised its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.